CART-WHEEL.org: An Ethically Approved Onlin Check for Database for Patient-Entered Data to Facilitate Rare Cancer Research

Damien Kee, MBBS^{1,2,3}; Clare Parker, MD^{1,2}; Susie Bae, MBBS²; Katherine M. Tucker, MBBS⁴; Michelle Harrison, MBBS^{5,6}; Ibrahim Tohidi-Esfahani, BMed^{7,8}; Marita Black, BSc⁹; Rachel Delahunty, MBBS²; Sumitra Ananda, MBBS^{1,2,3,10}; Michael Friedlander, MBCHb¹¹; Heather E. Cunliffe, PhD¹²; Peter Gibbs, MD^{1,2}; Jayesh Desai, MBBS²; Judith Trotman, MBChB^{7,8}; and Clare L. Scott, MD, PhD^{1,2,3,10,13}

PURPOSE Rare cancers are challenging for researchers, as clinicians and scientists have difficulty recruiting sufficient patient cases to power studies appropriately. Likewise, patients often are frustrated by a lack of specific information or evidence base for their cancer and, although eager to participate in research, have limited opportunities. We established CART-WHEEL.org, an online patient-entered database, to directly engage patients in the research process, collect rare cancer data, and facilitate their entry into additional research.

PATIENTS AND METHODS Patients access CART-WHEEL.org directly online. Clinical information is collected from users via a streamlined questionnaire developed collaboratively with consumer groups to ensure accessibility and relevance. Data collected include the following: patient demographics, comorbidities, and risk factors and tumor diagnostic, biomarker, and treatment history. Patients can download a medical summary for personal use; consent for research use of data; and indicate willingness to be contacted about other research or clinical trials. We describe data collected to date and its validation, and we provide examples of how CART-WHEEL.org can facilitate rare cancer research.

RESULTS From January 2010 to March 2018, 558 patients provided consent and entered their rare cancer data. One hundred distinct rare tumor types and patients from 22 countries were included. Validation of data entered by 21 patients with sarcoma against a hospital database demonstrated accuracy sufficient to facilitate future research in key fields, such as tumor site (95%) and histopathologic diagnosis (90%). Examples of CART-WHEEL-based disease-specific projects, subsequent recruitment to other rare cancer projects, and rare cancer patient cases of interest are described.

CONCLUSIONS Online platforms like CART-WHEEL.org can engage consumers directly, facilitating collection of patient-entered rare cancer data for hypothesis generation, and connect patients with researchers to enable specific rare cancer research and clinical trials.

JCO Clin Cancer Inform 4:136-146. $\ensuremath{\textcircled{O}}$ 2020 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License @

INTRODUCTION

Defined by an incidence of < 6 per 100,000 personyears, rare cancers account for one fifth of cancer diagnoses and one third of cancer deaths, so they are a paradoxically common problem.¹ However, treatment of most rare cancers is plagued by limited evidence, as research is complicated by small patient numbers and a lack of dedicated resources that have contributed to a slower rate of improvement in survival compared with more common cancers.² The aims of better identifying patients with rare cancer and increasing their participation in clinical trials and basic research require novel platforms; international collaboration; and involvement from all stakeholders, including patients.³⁻⁵ Involvement of patients in cancer research is an important component of health services that has been gaining traction in recent years.⁶⁻⁹ Patients with rare diseases (including cancers) reportedly use the Internet disproportionately more than those with common diseases to address knowledge gaps and connect with other patients for support and information.¹⁰ Similarly, researchers of rare cancer can better capitalize on modern connectivity through consumer-driven databases available online to overcome the barrier of geography when investigating diseases with low incidence.²

The Centre for Analysis of Rare Tumors, or CART-WHEEL.org, is a Web-based platform that can help bridge the gap between patients and researchers. It allows patients to enter and share their clinical data and to consent to being contacted for additional research opportunities to facilitate rare tumor research.¹¹ It is supported by the not-for-profit data-linkage platform BioGrid Australia and by cancer patient

ASSOCIATED CONTENT

Appendix

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on January 30, 2020 and published at

ascopubs.org/journal/ cci on February 21, 2020: DOI https://doi. org/10.1200/CCI.19. 00085





CONTEXT

Key Objective

Online platforms have the potential to facilitate patient engagement in research, with particular benefits for traditionally underserved populations. We developed CART-WHEEL.org to assess whether an online database could be used to collect natural history data directly from patients with rare cancers and streamline their enrollment into specific research programs and clinical trials.

Knowledge Generated

Since enrolment, CART-WHEEL.org has collected patient data on more than 100 rare tumor types from patients living in 22 different countries and has directed more than 10% of participants with solid tumors into traditional biomarker and genomic research. In partnership with the International Waldenström's Macroglobulinemia Foundation, the platform hosts a growing database of more than 382 patients with Waldenström's macroglobulinemia.

Relevance

Unlike traditional hospital-based research, online platforms are not limited by geography and can synergize with existing online patient networks to accelerate recruitment of patients with rare diseases, including cancer, to facilitate research.

organizations, such as Rare Cancers Australia. CART-WHEEL.org was designed to assist patients, their next-of-kin, or their guardians to participate in rare tumor research. This report describes the CART-WHEEL.org database and consent process; outlines the validation of the patient-entered data; provides an example of how the database has been used to facilitate research into rare tumors; and describes clinical patient cases that highlight the plight currently faced by patients with rare cancer as well as progress made in the field.

PATIENT AND METHODS

CART-WHEEL.org provides an online platform linking patients with a rare cancer to relevant researchers for recruitment to specific clinical trials or research studies. Potential participants locate CART-WHEEL.org directly or via associated consumer groups, learn about processes involved in rare tumor research, and enter their medical information into a streamlined online questionnaire. Collected clinical information is stored securely, and patients can download a summary of their entered information. Approved researchers involved in rare cancer projects can request de-identified aggregate data. Expert consumers and consumer groups have an ongoing role in developing and testing the questionnaire and consent process to optimize usability and minimize barriers to participation.

The project was approved by the Melbourne Health Human Research Ethics Committee (MH-2007.270). To our knowledge, this project is the first ethically approved, academically overseen, internationally available database for patient-entered clinical, molecular, and familial data covering all rare cancer types.

Database Design and Hosting

Data collected through CART-WHEEL.org are stored in the Rare Tumor Database managed by BioGrid Australia. Participant identifiers and clinical information are stored in separate databases. BioGrid Australia has completed extensive work in overcoming barriers to safeguard privacy and ethics while allowing data linkages to facilitate collaborative medical and bioinformatics research.¹²

Patient-entered clinical data are collected through a streamlined questionnaire, with data fields selected to collect information about the natural history of rare tumors and their management to provide a foundation for future rare cancer research. Other rare disease platforms that facilitate patient-entered data have demonstrated advantages, including decreased burden on clinical teams and ease of data collection and access.¹³ Collected data fields include the following: demographic information (age, sex, country of residence); tumor diagnostic information (date of diagnosis, primary site, tumor histologic type, genetic testing); treatment information (surgeries and biopsies, radiation therapies, drug therapy received, including drug access-such as participation in clinical trials, and adverse effects experienced); risk factors for the development of tumors (family history of cancer, germline mutation testing, history of an inherited familial cancer syndrome, smoking and alcohol consumption); and comorbidities. Comorbidities are recorded using a patient-friendly version of the Charlson comorbidity index.¹⁴ The guestionnaire allows development of disease-specific projects, with custom fields that allow approved researchers and consumer groups to develop their own projects within the CART-WHEEL.org database.

Patient Consent

The consent process has been designed to minimize barriers for participant involvement.¹² Patients originally were provided with participant information online and a consent form that could be printed, completed, and returned to CART-WHEEL.org by e-mail or post. Online push button consent was implemented in June 2017. The consent process is dynamic, allowing for different levels of

Downloaded from ascopubs.org by 128.250.252.193 on March 25, 2021 from 128.250.252.193 Copyright © 2021 American Society of Clinical Oncology. All rights reserved.

involvement and patient-initiated modifications at any time. The base level of consent permits the storage of consumers' self-entered medical information in the Rare Tumor Database and its deidentified use by approved researchers. Patients can grant permission to be contacted by BioGrid Australia about other relevant ethically approved research projects or clinical trials; allow a nominated clinician to enter, view, and edit their data, which is stored in parallel to their own entered data; and provide permission for BioGrid Australia to obtain copies of histopathology reports or other supporting medical information for data validation.

Data Quality Validation

Quality of patient-entered data was assessed in a cohort of patients attending a sarcoma clinic that had an existing clinical database overseen by a trained data manager, allowing data validation. Attendees to the clinic were recruited during 5 months by a clinical research fellow who provided information about CART-WHEEL.org and the validation study. Those interested were provided with a paper-based CART-WHEEL.org brochure, patient information and consent form, and recruitment letter describing this substudy. Twenty-one patients registered with CART-WHEEL.org, entered data, and provide consent. For all patients, selected data fields (demographics, tumor site and histology, date of diagnosis, and treatment) were compared for accuracy, and the hospital sarcoma database was used as the gold standard.

Data Access for Researchers

Researchers involved in an ethically approved rare cancer project can apply to access data held in CART-WHEEL.org using the BioGrid Australia standard process. This process is described in detail at BioGrid Australia online.¹⁵

RESULTS

Accrual and Participant Demographics

From January 2010 to March 2018, 881 patients registered, and 558 patients completed the consent process and entered data into the questionnaire (Fig 1). From 2010 until 2015, recruitment averaged 72 registrations per year; recruitment increased to 116 in 2016 and to 311 in 2017. This increase correlated with recruitment to the substudy, Waldenström's Macroglobulinemia Study Involving CART-WHEEL.org, or Whimsical (described in the Projects section). The average time from diagnosis to registration for patients who used CART-WHEEL.org was 2.9 years (range, 0-33.4 years).

Table 1 lists the demographics of the patients who consented to CART-WHEEL.org use. The largest proportion of patients (34%) were age 60-69 years, and 18% of patients were younger than age 50. There were more women (54%) than men (42%); 4% of patients did not specify sex. At the time of this analysis, CART-WHEEL.org captured patient information from 22 countries; the majority were from Australia (48%) and the United States (23%).




FIG 1. Consents and Registrations to CART-WHEEL.org. From January 2010 to January 2018, 881 patients registered to CART-WHEEL.org. A total of 585 patients consented to the use of their data for research purposes. An increase in recruitment in 2017 relates to targeted recruitment via CART-WHEEL.org for the Waldenström's Macroglobulinemia Whimsical study.

Of the 558 consenting patients, 490 (88%) entered a diagnosis of a rare malignant tumor (Fig 2). Forty-one patients (7%) entered a diagnosis of a tumor histology with an incidence of > 6 per 100,000 (potentially including rare subtypes of more common tumors), 9 patients entered a benign diagnosis, and 18 patients did not specify a histologic diagnosis. All 558 patients were included in the demographic analysis. Only the patients who entered a diagnosis of a rare malignant tumor were included in analysis of time points and treatment events.

CART-WHEEL.org collected data representing 100 different tumor types, including 82 rare malignant tumor types, 4 rare benign tumor types, and 14 tumor types that were not rare (one of which was benign). Figure 3 shows the spectrum of tumor types represented by these 558 patients, and Appendix Table A1 (online only) details the spread of diagnoses. Two patients had 2 diagnoses, such that data were collected for 560 tumors. Half of patients (54%) had a hematologic malignancy, predominantly Waldenström's macroglobulinemia (WM; 53%), reflecting strong consumer engagement for disease-specific substudies via the Whimsical project. The next most common cancer types were bone and soft tissue tumors (62 of 560 patients, or 11%) and gynecologic cancers (55 of 560 patients, or 10%). Table 2 shows the key time points and treatment events recorded by the 490 patients who had rare tumor diagnoses. For patients with solid tumors, only 11% reported receiving more than one line of chemotherapy, and only 5% had been included in a clinical trial. These data may reflect the short time since diagnosis of the cohort or may represent real-world data, because many patients may not be treated at a major cancer center.

Data Validation Against a Hospital Sarcoma Database

One hundred fifty-one patients attending a tertiary hospital sarcoma clinic were approached by a research fellow about

TABLE 1. Demographics of Patients Who Consented to CART-WHEEL.org

Characteristic	No. (%) of Patients (N = 558)
Age at registration, years	
Median (range)	62 (19-85)
Distribution	
< 30	13 (2)
30-39	28 (5)
40-49	62 (11)
50-59	115 (21)
60-69	189 (34)
70-79	102 (18)
80-89	18 (3)
Not specified	31 (6)
Sex	
Female	302 (54)
Male	236 (42)
Not specified	20 (4)
No. of different countries represented	22
Country most lived in	
Australia	267 (48)
United States	130 (23)
New Zealand	34 (6)
United Kingdom	30 (5)
Canada	28 (5)
The Netherlands	16 (3)
South Africa	4 (1)
Germany	3 (1)
France	3 (1)
Other or not specified	43 (8)

the data validation project; 127 patients (84%) provided verbal agreement to participate, and 22 patients (17%) completed both the questionnaire and the written consent process. One patient subsequently diagnosed with a benign soft tissue tumor was excluded from this analysis. Five shared questions between the CART-WHEEL.org questionnaire and the hospital sarcoma database were compared for accuracy (Tables 3 and 4). These concerned the diagnosis and management of sarcoma and were considered most relevant for researchers wanting to generate a future rare cancer research project. Date of diagnosis was accurately reported by 18 patients (86%). Incorrect dates could be explained by delay between initial investigations and confirmation of the diagnosis, or by patients who underwent multiple biopsies and were unsure which was diagnostic. A correct diagnosis broadly fitting with sarcoma was entered by 19 patients (90%), with 15 (71%) entering the same histopathologic diagnosis as contained in the hospital database. Primary site of disease was accurately recorded by 20 patients (95%). Both the hospital sarcoma database and the CART-WHEEL.org questionnaire collected personal and family cancer history to identify potential genetic risks. Fifteen patients (71%) entered family history data consistent with the hospital sarcoma database, and some provided additional family history not previously recorded. Overall, 96% (representing 49 of 51 patients) of the patient-entered data about treatment was accurate, reflecting the ability of patients to understand and accurately input information about complex treatment pathways.

CART-WHEEL.org Projects

A key aspect of CART-WHEEL.org is the ability for clinicians and patient-researchers to collaborate in developing ethically approved disease-specific projects with customized questions. This feature allows consumer groups to play a more active role in research and accelerate data collection for specific rare cancers. An example project is Whimsical, which is led by clinician and expert consumer investigators in partnership with the International Waldenström's Macroglobulinemia Foundation and its Australian affiliate, WMozzies. WM is a very rare cancer, with an incidence of < 0.3 per 100,000 making it difficult to study using conventional methodology. However, its readily trackable biomarkers, hemoglobin and immunoglobin M, are easily recognized and recorded by patients. For Whimsical, patient investigators were integral in designing and testing WM-specific questions that track and display these biomarkers and in the decision to include the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 into the general CART-WHEEL.org questionnaire. Active promotion by consumer groups resulted in strong recruitment of patients with WM to CART-WHEEL.org. An early data analysis was presented by Tohidi-Esfahani et al¹⁶ at the 2017 meeting of the American Society of Hematology. At that time, a total of 206 patients with WM (137 of whom were recruited within a 10-week period) had provided data about symptoms, biomarkers, and treatment. The ongoing project reached 382 participants in April 2019 and has an eventual accrual target of 1,000 patients. When completed, the project aims to provide a comprehensive international description of realworld treatment patterns for this rare disease.

Referral to Subsequent Rare Cancer Research Projects

Thirty-one participants identified through CART-WHEEL. org subsequently have been contacted and enrolled in additional rare cancer research via the Walter and Eliza Hall Medical Research Institute's Stafford Fox Rare Cancer Program. This second program includes a remote consent option that enables CART-WHEEL.org participants, with appropriate consent, to be invited for inclusion in a traditional cancer biomarker program involving detailed analysis of their biospecimens. This program includes nextgeneration sequencing and, if they are undergoing surgery or biopsy, the development of long-lived cell lines. The

Downloaded from ascopubs.org by 128.250.252.193 on March 25, 2021 from 128.250.252.193 Copyright © 2021 American Society of Clinical Oncology. All rights reserved.




FIG 2. Patients registered and consented to CART-WHEEL.org. All patients who consented and entered data were included in demographic analysis. Only patients with a rare malignant tumor diagnosis were included in analysis of other events. ICD-O, International Classification of Diseases for Oncology.

purpose of this preclinical research is to improve translational opportunities for all patients with rare cancers.¹⁷

A quality assurance review of the clinical data of the first 100 patient cases enrolled in the CART-WHEEL.org database revealed that these data could help generate new hypotheses and research directions. For instance, of the 24 GI and genitourinary neuroendocrine tumors so far accrued to CART-WHEEL.org, five patient cases have family histories of neuroendocrine tumors in which germline testing of known predisposition genes had not yet revealed a mutation. In addition, three patient cases have relatives with spindle cell carcinomas in whom additional investigation




FIG 3. The types of rare tumors reported by patients consented to CART-WHEEL.org. More than half of the patients consented to CART-WHEEL.org reported having a hematologic malignancy, reflecting consumer support of the Whimsical project specific to Waldenström's macroglobulinemia. Sarcoma and gynecologic rare cancers were the next most common types of cancers. An additional 35 rare tumor types were reported.

could be warranted. One of the hallmarks of an unrecognized germline mutation is a family history that includes rare tumors occurring in more than one individual or multiple primary tumors occurring within an individual, so CART-WHEEL.org can provide a fertile platform for discovery of novel cancer predisposition genes.

DISCUSSION

In 2010, we launched CART-WHEEL.org with the aim of facilitating access for patients with rare cancer and consumer groups to rare cancer research to generate meaningful real-world data for these under-researched conditions. Since launch, more than 558 patients with more than 100 rare tumor types have entered their data and provided consent for its use in research. This includes an international database of patients with WM that, with 382 patients registered, represents nearly 130 million personyears in accrual. More than 10% of participants with solid tumors subsequently have been recruited into traditional biomarker and genomic research.

Decentralizing access to research for patients with rare cancers complements existing strategies of centralizing expertise and virtual networks typified by the development of European Reference Networks for Rare Adult Solid Cancers. A key recommendation of the Cancer Moonshot initiative has been the development of networks to facilitate direct patient engagement aiming to improve research involvement of currently underserved populations, such as rural or minority populations and those with rare cancers.¹⁸ The NCI Rare Tumor Patient Engagement Network currently oversees two major projects: The NCI Comprehensive Oncology Network Evaluating Rare Central Nervous System Tumors (ie, NCI-CONNECT) and MyPART: My Pediatric and Adult Rare Tumor Network. Like CART-WHEEL.org, these programs partner with patient advocacy groups and use online surveys and remote consent to enroll participants, collect natural history data, and preregister patients for rare cancer research and clinical trials. Unlike traditional hospital databases, online platforms are not limited by geography and can synergize with existing online patient networks to expand recruitment. Although early users of CART-WHEEL.org predominantly were based in Australia, partnerships with international consumer groups have resulted in an increasingly global demographic. Online recruitment and participant self-entry of data also minimize costs associated with a traditional data manager-run databases, making a project like this viable.

The limitations of this approach must be considered when making use of the collected data. Patient self-enrollment will lead to biases in recruitment. For online platforms, the recruited demographic will more closely reflect those people seeking help on the Internet and (in the case of CART-WHEEL.org) those who are proficient in English. Patients with very good or very poor outcomes may be less likely to enroll—the former because they are cured and are
 TABLE 2.
 Analysis of 490 Patients With a Rare Malignant Tumor Type Enrolled in CART-WHEEL.org

	Patients by Tumor Type						
	Solid	Tumor	Hematologic Tumor				
Variable	No.	%	No.	%			
Total	191	39.0	299	61.0			
Median (range) age at diagnosis, years	53 (1	17-77)	60 (24-83)			
Median time from diagnosis to registration, months (years)	18 (1	1.5)	47 (3.9)			
Surgical event							
No. of biopsies							
0	19	10.0	32	10.7			
1	143	74.9	212	70.9			
2-3	27	14.1	41	13.7			
≥ 4	2	1.0	14	4.7			
No. of surgeries							
0	39	20.4	293	98.0			
1	118	61.8	6	2.0			
≥ 2	34	17.8	0	0.0			
Treatment event							
No. of drug therapy events							
0	85	44.5	106	35.5			
1	80	41.9	104	34.8			
2-3	21	11.0	54	18.1			
≥ 4	5	2.6	35	11.71			
No. of radiation events							
0	121	63.4	292	98			
1	60	31.4	6	2.0			
≥ 2	10	5.2	1	0.01			
Participation in clinical trials							
No	180	94.2	262	87.6			
Yes	11	5.7	37	12.4			
No. of tumor genes tested							
0	168	88.0	246	82.3			
1	20	10.5	50	16.7			
≥ 2	3	1.6	3	1.0			
Family history							
No. of family cancer events							
0	73	38.2	96	32.1			
1	57	29.8	113	37.8			
2-3	48	25.1	79	26.4			
≥ 4	13	6.8	11	3.7			
No. of family genes tested							
0	151	79.0	272	91.0			
1	36	18.9	16	5.4			
≥2	4	2.1	11	3.7			

NOTE. Of the 490 patients, 39% had a solid tumor, of whom 75% or more had either a biopsy or surgical specimen that may have been available for future research. Of these, 55% reported having had one or more lines of systemic treatment, and 37% reported having radiation treatment (with median time from diagnosis to registration of 1.5 years). For the 61% of patients with a hematologic malignancy, 89% reported having had a biopsy, and 64% had one or more lines of therapy.

	Data Category Comparison	No.	%
Female1362Diagnosis01886Date of diagnosis (within 30 days)1886Anatomic site095Site of primary2095Treatment1571Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Demographics		
DiagnosisDate of diagnosis (within 30 days)1886Anatomic site2095Site of primary2095Treatment1571Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Median (range) age at presentation, years	54 (2	0-74)
Date of diagnosis (within 30 days)1886Anatomic site	Female	13	62
Anatomic siteSite of primary2095Treatment95Surgery1571Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Diagnosis		
Site of primary2095Treatment1571Surgery1571Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Date of diagnosis (within 30 days)	18	86
TreatmentSurgery15Chemotherapy17Radiation17Data not entered4Histopathologic diagnosisExact histopathologic diagnosis15Broad category of histopathologic diagnosis1990	Anatomic site		
Surgery1571Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis571Exact histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Site of primary	20	95
Chemotherapy1781Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Treatment		
Radiation1781Data not entered419Histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Surgery	15	71
Data not entered419Histopathologic diagnosis1571Exact histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Chemotherapy	17	81
Histopathologic diagnosis 15 71 Broad category of histopathologic diagnosis 19 90	Radiation	17	81
Exact histopathologic diagnosis1571Broad category of histopathologic diagnosis1990	Data not entered	4	19
Broad category of histopathologic diagnosis 19 90	Histopathologic diagnosis		
	Exact histopathologic diagnosis	15	71
Inaccurate 1 5	Broad category of histopathologic diagnosis	19	90
	Inaccurate	1	5
Data not entered 1 5	Data not entered	1	5

not seeking additional health information, and the latter because they are too unwell or have died. Enrollment therefore may be skewed toward certain cancer types or prognostic subgroups or to those who have responded exceptionally well (or poorly) to therapy. Although these factors may be difficult to control across cancer types, within specific cancer histologies, potential biases may be more predictable and can enrich for interesting subgroups that allow focused analysis.

A second concern, relating to patient self-entry of data, involves ensuring data accuracy, completeness, and followup. In our validation cohort, we demonstrated that participants who self-select to enroll and consent to CART-WHEEL.org were able to complete key data fields with a high degree of accuracy. The low completion rate of 17% of initially interested participants was disappointing. Identified factors contributing to this low rate included that only a single approach for the majority of participants (94%) and potential difficulties in completing the questionnaire, which may reflect usability or lack of patient knowledge but also may positively select for participants more able to provide higher-quality data. Of note, this low participation rate still exceeds international benchmarks for clinical trial participation in the adult cancer population.^{19,20} However, in recognition that complete and ongoing validation would be difficult and beyond the resources of this project, a protocol amendment has allowed participants to provide consent for CART-WHEEL.org to contact a nominated clinician and obtain access to medical records, including histology reports. This allows for a targeted approach to data validation so that patient cases potentially relevant to

JCO Clinical Cancer Informatics

Kee et al

			Data Match	
CART-WHEEL.org Tumor	Hospital Database Tumor	Exact	Broadly Correct	Inaccurate or Not Entered
PNET	PNET	Yes		
Atypical lipoma	Atypical lipoma	Yes		
Retroperitoneal liposarcoma	Retroperitoneal liposarcoma	Yes		
Sarcoma within adductor mm	LMS		Yes	
Chondrosarcoma	Chondrosarcoma	Yes		
Dermatofibrosarcoma protuberans	DFSP	Yes		
Paraosteal osteogenic sarcoma	Mixoid liposarcoma			Yes
Chondrosarcoma	Chondrosarcoma	Yes		
Pleomorphic sarcoma, high grade ^a	Soft tissue tumor without additional specification		Yes	
LMS	LMS	Yes		
Soft tissue sarcoma	LMS		Yes	
GIST	GIST	Yes		
Uterine LMS	Uterine LMS	Yes		
PNET, Ewing's sarcoma	PNET	Yes		
	Metastatic myogenic sarcoma			Yes
Liposarcoma	Liposarcoma	Yes		
Giant cell tumor of bone	Giant cell tumor	Yes		
Liposarcoma	Liposarcoma	Yes		
LMS	LMS	Yes		
Chondrosarcoma	Chondrosarcoma	Yes		
Sarcoma, not otherwise specified	LMS		*	

Abbreviations: DESP, dermatofibrosarcoma protuberans; GIST, GI stromal tumor; LMS, leiomyosarcoma; PNET, primitive neuroectodermal tumor. ^aDiagnosis not updated after multidisciplinary meeting in hospital database but known by and recorded correctly by patient.

a specific research question or secondary research program can be audited selectively.

There is precedence for clinical information collected by lay people to generate meaningful findings for rare cancers. The International Hemangioendothelioma, Epithelioid Hemangioendothelioma, and Related Vascular Disorders (ie, HEARD) Support Group collected clinical data from more than 200 of its members that was analyzed by researchers and published in 2011.²¹ This report continues to be one of the largest clinical data sets for these rare vascular tumors, providing key information relating to disease demographics, clinical patterns, and outcomes, and continues to be highly cited today.²²

AFFILIATIONS

¹Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia ²Peter MacCallum Cancer Centre, Melbourne, VIC, Australia ³Department of Medicine, University of Melbourne, Melbourne, VIC,

⁴Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, VIC, Australia

In summary, CART-WHEEL.org is an online database that facilitates research access for patients with rare cancers. It provides a cost-effective platform where patients can share clinical information to help generate natural history data and to match patients with research projects. CART-WHEEL.org can overcome the barriers of geography and time of diagnosis when recruiting patients to research. The dynamic consent process allows additional verification of data, such as histopathology, if required. Project-specific data collected via CART-WHEEL.org show that, when a relevant study is available, the recruitment of patients with that rare tumor increases promptly. This platform can help patients and patient groups connect with researchers, leading to greater research opportunities.

Data Match

 ⁵Chris O'Brien Lifehouse, Camperdown, NSW, Australia
 ⁶Liverpool Hospital, Liverpool, NSW, Australia
 ⁷School of Medicine, University of Sydney, Sydney, NSW, Australia
 ⁸Hematology department, Concord Repatriation General Hospital, Concord, NSW, Australia
 ⁹CART-WHEEL (BioGrid Australia), Royal Melbourne Hospital, Parkville, VIC, Australia

Australia

¹⁰Royal Women's Hospital, Parkville, VIC, Australia

 $^{11}\mathrm{Prince}$ of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia

¹²Department of Pathology, University of Otago, Dunedin, New Zealand ¹³Department of Obstetrics and Gynecology, University of Melbourne, Melbourne, VIC, Australia

CORRESPONDING AUTHOR

Clare L. Scott, MD, PhD, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia; Twitter: @CARTWHEELcancer; e-mail: scottc@wehi.edu.au.

EQUAL CONTRIBUTION

D.K. and C.P. contributed equally to this work.

PRIOR PRESENTATION

Presented in part at the COSA 42nd Annual Scientific Meeting, Hobart, Australia, November 17-19, 2015.

SUPPORT

Supported by grants for consumer participation from the Victorian Cancer Agency, the Royal Melbourne Hospital Foundation and the Picchi Brothers Foundation; and fellowships from the Stafford Fox Medical Research Foundation (C.L.S.); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to C.L.S.); and the Victorian Cancer Agency (Clinical Fellowships CRF10-20 and CRF16014 to C.L.S.). This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme.

AUTHOR CONTRIBUTIONS

Conception and design: Damien Kee, Susie Bae, Katherine M. Tucker, Ibrahim Tohidi-Esfahani, Jayesh Desai, Judith Trotman, Clare L. Scott **Administrative support:** Susie Bae, Marita Black

Financial support: Judith Trotman, Clare L. Scott

Collection and assembly of data: Damien Kee, Clare Parker, Susie Bae, Ibrahim Tohidi-Esfahani, Marita Black, Rachel Delahunty, Sumitra Ananda, Heather E. Cunliffe, Peter Gibbs, Judith Trotman, Clare L. Scott **Data analysis and interpretation:** Damien Kee, Clare Parker, Susie Bae, Michelle Harrison, Rachel Delahunty, Sumitra Ananda, Michael Friedlander, Heather E. Cunliffe, Peter Gibbs, Jayesh Desai, Judith Trotman, Clare L. Scott

Manuscript writing: All authors

Final approval of manuscript: All authors

Provision of study material or patients: Susie Bae, Michelle Harrison, Peter Gibbs, Jayesh Desai, Judith Trotman, Clare L. Scott

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs. org/cci/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Katherine M. Tucker

Travel, Accommodations, Expenses: AstraZeneca (OPTIONAL) Uncompensated Relationships: AstraZeneca

Michael Friedlander

Honoraria: AstraZeneca, MSD, Lilly, Takeda Consulting or Advisory Role: AstraZeneca, MSD, AbbVie, Lilly, Takeda Speakers' Bureau: AstraZeneca Research Funding: BeiGene (Inst)

Peter Gibbs

Honoraria: Roche, Amgen, Merck, Sirtex Medical, SERVIER, MSD Oncology

Research Funding: Roche (Inst), Ventana Medical Systems (Inst), Amgen (Inst), Merck Serono (Inst)

Travel, Accommodations, Expenses: SERVIER

Jayesh Desai

Consulting or Advisory Role: Lilly, Eisai, BeiGene, Biocon, Amgen (Inst) **Research Funding:** Roche (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Bionomics (Inst), BeiGene (Inst), Lilly (Inst), Bristol-Myers Squibb (Inst), AstraZeneca (Inst), MedImmune (Inst)

Judith Trotman

Research Funding: BeiGene (Inst), Roche (Inst), Genentech (Inst), Pharmacyclics (Inst), Janssen-Cilag (Inst), Takeda (Inst), Celgene (Inst) Travel, Accommodations, Expenses: Roche, Genentech

Clare L. Scott

Research Funding: Roche, Genentech, Clovis Oncology, Sierra Oncology, Eisai

Patents, Royalties, Other Intellectual Property: Royalty agreement for venetoclax (Inst) Expert Testimony: AstraZeneca Travel, Accommodations, Expenses: AstraZeneca

Other Relationship: Clovis Oncology

No other potential conflicts of interest were reported.

REFERENCES

- 1. Gatta G, van der Zwan JM, Casali PG, et al: Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer 47:2493-2511, 2011
- 2. Gaddipati H, Liu K, Pariser A, et al: Rare cancer trial design: Lessons from FDA approvals. Clin Cancer Res 18:5172-5178, 2012
- 3. Dockser Marcus A: To make progress in rare cancers, patients must lead the way. J Clin Oncol 27:2575-2577, 2009
- 4. Blay J-Y, Coindre J-M, Ducimetière F, et al: The value of research collaborations and consortia in rare cancers. Lancet Oncol 17:e62-e69, 2016
- Nunn JS, Scott CL, Stubbs, JW, Cherry SF: Involving the public in rare cancer care and research: shaping the future for rare and uncommon cancers, in Raghavan D, Ahluwalia MS, Blanke CD, et al (eds): Textbook of Uncommon Cancer (ed 5). West Sussex, United Kingdom, Wiley-Blackwell, 2017, pp12-18.
- 6. Hubbard G, Kidd L, Donaghy E: Involving people affected by cancer in research: A review of literature. Eur J Cancer Care (Engl) 17:233-244, 2008
- 7. Bryant J, Sanson-Fisher R, Fradgley E, et al: A consumer register: An acceptable and cost-effective alternative for accessing patient populations. BMC Med Res Methodol 16:134, 2016
- 8. Callard F, Rose D, Wykes T: Close to the bench as well as at the bedside: Involving service users in all phases of translational research. Health Expect 15:389-400, 2012

Kee et al

- 9. Arain M, Pyne S, Thornton N, et al: Consumer involvement in cancer research: Example from a cancer network. Health Expect 18:1530-1542, 2015
- 10. Ziebland S, Chapple A, Dumelow C, et al: How the internet affects patients' experience of cancer: A qualitative study. BMJ 328:564, 2004
- 11. Bae S, Friedlander M, Scott CL: CART-WHEEL.org can facilitate research into rare gynecological tumors. Int J Gynecol Cancer 21:1517-1519, 2011
- 12. Merriel RB, Gibbs P, O'Brien TJ, et al: BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types. Hum Mutat 32:517-525, 2011
- Javaid MK, Forestier-Zhang L, Watts L, et al: The RUDY study platform: A novel approach to patient driven research in rare musculoskeletal diseases. Orphanet J Rare Dis 11:150, 2016
- 14. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
- 15. BioGrid Australia: Access data. https://www.biogrid.org.au/page/69/access-data.
- Tohidi-Esfahani I, Warden A, deNardis P, et al: Whimsical (Waldenström's Macroglobulinemia Study Involving CART-WHEEL): Empowering patients internationally to contribute patient-derived data for observational research. Blood 130:1502, 2017
- 17. Barker HE, Scott CL: Preclinical rare cancer research to inform clinical trial design. Nat Rev Cancer 19:481-482, 2019
- National Cancer Institute: Establish a network for direct patient engagement. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/ implementation/patient-engagement.
- Canadian Partnership Against Cancer: The 2016 cancer system performance report. https://www.systemperformance.ca/report/2016-cancer-systemperformance-report/.
- 20. Sinha G: United Kingdom becomes the cancer clinical trials recruitment capital of the world. J Natl Cancer Inst 99:420-422, 2007
- 21. Lau K, Massad M, Pollak C, et al: Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: Insights from an internet registry in the study of a rare cancer. Chest 140:1312-1318, 2011
- Rosenbaum E, Jadeja B, Xu B, et al: Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol doi:10.1038/ s41379-019-0368-8 [epub ahead of print on September 19, 2019].

APPENDIX

TABLE A1.	Type of Rare	Tumor Re	eported by	Patients Who	Consented	to CART-WHEEL.org
						Crudo Incidonos

Tumor Type	Crude Incidence per 100,000ª	R	В	No. (%) of Patient
Hematologic tumor	• •			299 (53)
Lymphoma lymphoplasmacytic/Waldenström's macroglobulinemia	< 1	R		297
Diffuse B lymphoma	4.32	R		2
Gynecologic tumor				55 (10)
Serous tumor		R		13
Of the ovary	< 5.95	R		8
Of the fallopian tube	0.17	R		4
Of the peritoneum	0.08	R		1
Mucinous ovarian tumor	< 5.95	R		9
Granulosa cell tumors of the ovary	0.13	R		9
Clear cell ovarian tumors	< 5.95	R		3
Germ cell tumors of the ovary	0.07	R		2
Uterine carcinosarcomas	0.4	R		3
Clear cell endometrial tumor	0.16	R		2
Other or unspecified rare ovarian tumor	< 5.95	R		4
Other rare uterine tumor		R		4
Other rare cervical tumor		R		4
Small cell carcinoma ovary	NA	R		2
Bone and soft tissue tumor				62 (11)
Leiomyosarcoma	< 4.71	R		13
Liposarcoma	< 4.71	R		7
Epithelioid hemangioendothelioma	< 4.71	R		8
Chondrosarcoma	< 4.71	R		6
Ewing's sarcoma/PNET	0.12	R		4
Dermatofibrosarcoma protuberans	< 4.71	R		2
Other or unspecified sarcoma	< 4.71	R		11
Osteosarcoma and other bone tumor	< 0.85	R		5
Desmoid tumor			В	4
Other benign soft tissue tumor			В	2
GI tumor				22 (4)
GI stromal tumor	0.3	R		10
Cholangiocarcinoma	1.35	R		3
Signet ring cell carcinoma of the appendix	< 0.11	R		3
Mucinous adenocarcinoma of the appendix	< 0.11	R		2
Other rare GI tumor		R		5
Neuroendocrine tumor	3.51			28 (5)
Carcinoid tumor	1.01	R		8
Neuroendocrine tumors of the pancreas	1.72	R		6
Medullary thyroid carcinoma	< 0.24	R		3
Neuroendocrine tumors of the cervix	< 0.9	R		3
Merkel cell carcinoma	0.19	R		1
Other neuroendocrine tumor	< 3.51	R		7

(Continued on following page)

Kee et al

TABLE A1. Type of Rare Tumor Reported by Patients Who Consented to CART-WHEEL.org (Continued)

Tumor Type	Crude Incidence per 100,000ª	R	В	No. (%) of Patients
Breast tumor				26 (5)
Mucinous breast carcinoma	< 3.06	R		1
Triple-negative breast tumor	< 50			15
Common or unspecified breast tumor	67.16			10
Other				31 (6)
Adenoid cystic carcinoma	< 0.96	R		5
Papillary thyroid carcinoma	5.07	R		3
Adrenal cortical carcinoma	0.22	R		3
Tumors of male genital organs	< 3.29	R		3
Salivary gland and other rare head and neck tumor	< 0.96	R		3
Ependymal tumor of CNS	0.21	R		3
Other rare CNS tumor		R		3
Rare lung tumor		R		3
Extracutaneous melanoma	< 0.70	R		3
Sebaceous carcinoma	< 0.30	R		2
Other not rare tumor				17 (13)
Other benign tumor type		R	В	2
Unspecified tumor type				18 (3)

NOTE. R indicates a rare tumor with incidence < 6/100,000; B represents tumors not considered malignant as classified by the ICD-0. Abbreviations: B, benign; ICD-0, International Classification of Diseases, Oncology; NA, not applicable; PNET, primitive neuroectodermal tumor; R, rare.

^aCrude incidence per 100,000 as classified by RARECARE (Gatta et al¹).